In the realm of the proteome, it’s shape rather than size that matters. Perth-based drug-discovery biotech Phylogica believes it has just about every possible molecular contingency covered. [ + ]

Drug delivery company Acrux is preparing for a late September float on the Australian Stock Exchange after filing its prospectus for an AUD$30 million IPO with the Australian Securities and Investment Commission yesterday. [ + ]

Despite capital raisings and exercise of options totalling $7.3 million during the year, Prima Biomed (ASX: PRR) is down to a cash balance of $2.8 million after posting a net loss of $4.9 million for the 2003-2004 financial year. [ + ]

Ventracor (ASX: VCR) yesterday posted an AUD$15.9 million net loss for the 2003-2004 financial year, up 70 per cent from last year's $9.4 million. [ + ]

The ancient Chinese pharmacopoeia has bequeathed Western medicine a dragon-slaying drug that promises to save the lives of up to two million people a year – half of them children under the age of two – in regions of the world haunted by drug-resistant strains of malaria. [ + ]

With all patients in the first stage of its Phase II HyCamp clinical trial escaping the gastrointestinal side-effects normally associated with standard colon cancer treatment irinotecan, Meditech (ASX:MTR) has announced it will forge ahead with second stage of its trial. [ + ]

New Zealand’s biotechnology industry wants the NZ government to establish a NZ$650-660 million, taxpayer-funded bridge between the nation’s research laboratories and its biotech business sector. [ + ]

One of the founders of Australia’s leading private wheat-breeding company has delivered a bleak prognosis for the commercial future of GM crops in Australia. [ + ]

Sleep apnoea and snoring device company Somnomed has closed its oversubscribed placement a week early, ahead of an expected float on August 27, 2004. [ + ]

The Victoria Prize was awarded today to Melbourne University physicist Prof Keith Nugent for his work on phase imaging and X-ray optics. [ + ]

If there’s money in muck, there’s also moolah in mania, according to molecular geneticist Dr Roland Toder, who built the Freiburg-based biotech company GeneScan Europe into the world’s leading gene-testing company for food and food ingredients. [ + ]

Biota (ASX: BTA) will relocate its US research operations to its new facilities in Melbourne in a bid to save costs. [ + ]

Chemeq (ASX: CMQ) has confirmed that its capital raising will include a placement of around AUD$10 million to institutions and sophisticated investors, as well as an underwritten rights offer of around $40 million to existing shareholders. [ + ]

Expressions of interest are being sought from Australian biotechnology companies interested in joining a trade mission to the United Kingdom and BioPartnering Europe 2004. [ + ]

Sydney-based proteomics pioneer Proteome Systems lodged a long-awaited prospectus for its initial public offering on the ASX with the Australian Securities and Investment Commission today. [ + ]